- AZURE-1 and AZURE-4 to form the basis of Mirum’s U.S. BLA Submission FOSTER CITY, Calif., March 05, 2026--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, ...
John Schwope, President and CEO for Simplified Clinical states, “As a contributing member of Microsoft’s AI Cloud Partner program, we share Microsoft’s vision for the future of clinical research data ...
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced completion of enrollment in the Phase 3 AZURE-1 study and completion of screening in the Phase 3 AZURE-4 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results